vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and CENTRAL PACIFIC FINANCIAL CORP (CPF). Click either name above to swap in a different company.

Bioceres Crop Solutions Corp. is the larger business by last-quarter revenue ($77.6M vs $72.9M, roughly 1.1× CENTRAL PACIFIC FINANCIAL CORP). CENTRAL PACIFIC FINANCIAL CORP runs the higher net margin — 28.4% vs -9.6%, a 38.0% gap on every dollar of revenue. On growth, CENTRAL PACIFIC FINANCIAL CORP posted the faster year-over-year revenue change (6.0% vs -16.8%). Over the past eight quarters, CENTRAL PACIFIC FINANCIAL CORP's revenue compounded faster (6.7% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

Central Pacific Bank (CPB) is an American regional commercial bank located throughout the state of Hawaii.

BIOX vs CPF — Head-to-Head

Bigger by revenue
BIOX
BIOX
1.1× larger
BIOX
$77.6M
$72.9M
CPF
Growing faster (revenue YoY)
CPF
CPF
+22.8% gap
CPF
6.0%
-16.8%
BIOX
Higher net margin
CPF
CPF
38.0% more per $
CPF
28.4%
-9.6%
BIOX
Faster 2-yr revenue CAGR
CPF
CPF
Annualised
CPF
6.7%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
BIOX
BIOX
CPF
CPF
Revenue
$77.6M
$72.9M
Net Profit
$-7.4M
$20.7M
Gross Margin
46.8%
Operating Margin
9.3%
Net Margin
-9.6%
28.4%
Revenue YoY
-16.8%
6.0%
Net Profit YoY
-20.2%
16.7%
EPS (diluted)
$-0.12
$0.78

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
CPF
CPF
Q1 26
$72.9M
Q4 25
$76.3M
Q3 25
$77.6M
$74.8M
Q2 25
$72.8M
Q1 25
$60.6M
$68.8M
Q4 24
$98.8M
$58.4M
Q3 24
$93.3M
$66.6M
Q2 24
$64.0M
Net Profit
BIOX
BIOX
CPF
CPF
Q1 26
$20.7M
Q4 25
$22.9M
Q3 25
$-7.4M
$18.6M
Q2 25
$18.3M
Q1 25
$-1.6M
$17.8M
Q4 24
$605.2K
$11.3M
Q3 24
$-6.2M
$13.3M
Q2 24
$15.8M
Gross Margin
BIOX
BIOX
CPF
CPF
Q1 26
Q4 25
Q3 25
46.8%
Q2 25
Q1 25
39.4%
Q4 24
42.0%
Q3 24
40.2%
Q2 24
Operating Margin
BIOX
BIOX
CPF
CPF
Q1 26
Q4 25
37.0%
Q3 25
9.3%
31.6%
Q2 25
32.8%
Q1 25
1.5%
32.8%
Q4 24
14.5%
23.0%
Q3 24
2.5%
25.6%
Q2 24
32.2%
Net Margin
BIOX
BIOX
CPF
CPF
Q1 26
28.4%
Q4 25
30.0%
Q3 25
-9.6%
24.8%
Q2 25
25.1%
Q1 25
-2.6%
25.8%
Q4 24
0.6%
19.4%
Q3 24
-6.6%
20.0%
Q2 24
24.7%
EPS (diluted)
BIOX
BIOX
CPF
CPF
Q1 26
$0.78
Q4 25
$0.85
Q3 25
$-0.12
$0.69
Q2 25
$0.67
Q1 25
$-0.02
$0.65
Q4 24
$0.00
$0.42
Q3 24
$-0.10
$0.49
Q2 24
$0.58

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
CPF
CPF
Cash + ST InvestmentsLiquidity on hand
$15.5M
Total DebtLower is stronger
$76.5M
Stockholders' EquityBook value
$288.3M
$593.9M
Total Assets
$734.9M
$7.5B
Debt / EquityLower = less leverage
0.13×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
CPF
CPF
Q1 26
Q4 25
Q3 25
$15.5M
Q2 25
Q1 25
$38.5M
Q4 24
$29.2M
Q3 24
$32.3M
Q2 24
Total Debt
BIOX
BIOX
CPF
CPF
Q1 26
$76.5M
Q4 25
$76.5M
Q3 25
$131.5M
Q2 25
$131.5M
Q1 25
$131.4M
Q4 24
$156.3M
Q3 24
$156.3M
Q2 24
$156.2M
Stockholders' Equity
BIOX
BIOX
CPF
CPF
Q1 26
$593.9M
Q4 25
$592.6M
Q3 25
$288.3M
$588.1M
Q2 25
$568.9M
Q1 25
$345.0M
$557.4M
Q4 24
$346.3M
$538.4M
Q3 24
$346.0M
$543.7M
Q2 24
$518.6M
Total Assets
BIOX
BIOX
CPF
CPF
Q1 26
$7.5B
Q4 25
$7.4B
Q3 25
$734.9M
$7.4B
Q2 25
$7.4B
Q1 25
$798.2M
$7.4B
Q4 24
$835.2M
$7.5B
Q3 24
$827.3M
$7.4B
Q2 24
$7.4B
Debt / Equity
BIOX
BIOX
CPF
CPF
Q1 26
0.13×
Q4 25
0.13×
Q3 25
0.22×
Q2 25
0.23×
Q1 25
0.24×
Q4 24
0.29×
Q3 24
0.29×
Q2 24
0.30×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
CPF
CPF
Operating Cash FlowLast quarter
$14.4M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
CPF
CPF
Q1 26
Q4 25
$97.5M
Q3 25
$14.4M
$22.2M
Q2 25
$34.3M
Q1 25
$23.3M
$20.4M
Q4 24
$-5.4M
$90.5M
Q3 24
$5.2M
$21.3M
Q2 24
$25.9M
Free Cash Flow
BIOX
BIOX
CPF
CPF
Q1 26
Q4 25
$92.3M
Q3 25
$21.4M
Q2 25
$32.3M
Q1 25
$19.6M
Q4 24
$75.4M
Q3 24
$15.6M
Q2 24
$21.3M
FCF Margin
BIOX
BIOX
CPF
CPF
Q1 26
Q4 25
121.0%
Q3 25
28.6%
Q2 25
44.3%
Q1 25
28.4%
Q4 24
129.2%
Q3 24
23.5%
Q2 24
33.2%
Capex Intensity
BIOX
BIOX
CPF
CPF
Q1 26
Q4 25
6.8%
Q3 25
1.2%
Q2 25
2.7%
Q1 25
1.3%
Q4 24
25.8%
Q3 24
8.5%
Q2 24
7.3%
Cash Conversion
BIOX
BIOX
CPF
CPF
Q1 26
Q4 25
4.26×
Q3 25
1.20×
Q2 25
1.88×
Q1 25
1.15×
Q4 24
-8.85×
7.98×
Q3 24
1.60×
Q2 24
1.64×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons